Shaker Investments LLC OH Decreases Stake in DexCom, Inc. $DXCM

Shaker Investments LLC OH lessened its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 16.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 39,977 shares of the medical device company’s stock after selling 7,760 shares during the period. DexCom comprises 1.1% of Shaker Investments LLC OH’s investment portfolio, making the stock its 28th biggest holding. Shaker Investments LLC OH’s holdings in DexCom were worth $2,690,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of DexCom by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 48,322,405 shares of the medical device company’s stock worth $4,218,063,000 after purchasing an additional 866,506 shares during the last quarter. Jennison Associates LLC raised its stake in DexCom by 9.4% in the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock valued at $1,005,367,000 after buying an additional 994,300 shares in the last quarter. Geode Capital Management LLC lifted its holdings in DexCom by 3.4% during the 2nd quarter. Geode Capital Management LLC now owns 10,766,356 shares of the medical device company’s stock worth $936,100,000 after buying an additional 358,617 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of DexCom by 22.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock worth $691,336,000 after acquiring an additional 1,868,241 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its holdings in shares of DexCom by 106.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company’s stock valued at $576,610,000 after acquiring an additional 3,410,858 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Wells Fargo & Company set a $93.00 target price on DexCom and gave the stock an “overweight” rating in a research note on Friday, October 31st. Mizuho raised their price objective on shares of DexCom from $75.00 to $78.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Evercore ISI started coverage on shares of DexCom in a report on Tuesday, November 25th. They issued an “in-line” rating and a $68.00 target price for the company. The Goldman Sachs Group dropped their target price on shares of DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a research report on Wednesday, October 1st. Finally, Royal Bank Of Canada dropped their price objective on DexCom from $100.00 to $85.00 and set an “outperform” rating on the stock in a report on Friday, October 31st. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.61.

Insider Activity

In related news, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the transaction, the director directly owned 27,031 shares in the company, valued at $1,569,690.17. This trade represents a 3.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Richard Alexander Collins sold 3,948 shares of the company’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $55.17, for a total transaction of $217,811.16. Following the transaction, the director owned 37,994 shares of the company’s stock, valued at approximately $2,096,128.98. The trade was a 9.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 7,866 shares of company stock valued at $448,177. Company insiders own 0.32% of the company’s stock.

DexCom Stock Up 0.2%

Shares of NASDAQ:DXCM opened at $67.57 on Friday. The stock has a market cap of $26.35 billion, a P/E ratio of 37.54, a P/E/G ratio of 1.45 and a beta of 1.51. The firm has a fifty day moving average price of $64.07 and a 200 day moving average price of $73.11. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.56 and a quick ratio of 1.38. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $93.25.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same period in the previous year, the business posted $0.45 earnings per share. DexCom’s quarterly revenue was up 21.6% on a year-over-year basis. Sell-side analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.